KeyCorp Issues Pessimistic Forecast for LifeMD (NASDAQ:LFMD) Stock Price

LifeMD (NASDAQ:LFMD) had its price target dropped by equities researchers at KeyCorp from $12.00 to $8.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price target suggests a potential upside of 97.29% from the company’s current price.

LFMD has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. B. Riley decreased their price objective on LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Lake Street Capital dropped their target price on LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. BTIG Research reduced their price target on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, LifeMD currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

LifeMD Price Performance

Shares of NASDAQ LFMD traded down $0.04 during mid-day trading on Wednesday, reaching $4.06. The company had a trading volume of 326,516 shares, compared to its average volume of 1,532,432. The company has a 50-day moving average price of $6.01 and a two-hundred day moving average price of $8.68. The stock has a market cap of $192.28 million, a PE ratio of -24.09 and a beta of 1.57. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. LifeMD has a 1-year low of $3.43 and a 1-year high of $15.84.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $60.17 million during the quarter, compared to analysts’ expectations of $62.07 million. During the same quarter in the prior year, the company earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts anticipate that LifeMD will post -0.56 earnings per share for the current year.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider directly owned 605,000 shares in the company, valued at $3,581,600. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 18.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its holdings in LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock worth $49,000 after purchasing an additional 1,351 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in LifeMD by 148.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock valued at $50,000 after purchasing an additional 2,185 shares during the last quarter. Quarry LP bought a new position in shares of LifeMD in the third quarter valued at approximately $52,000. Tower Research Capital LLC TRC lifted its stake in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after buying an additional 2,452 shares during the last quarter. Finally, King Wealth Management Group acquired a new stake in shares of LifeMD in the third quarter worth $68,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.